CellFE’s platform enables efficient multiplex CRISPR-Cas9 editing to engineer T cells

Managing toxicity and specificity of cell therapies relies on complex gene-editing mechanisms, requiring co-delivery of multiple gene-editing molecules. CellFE’s platform demonstrated the capability to co-deliver multiple CRISPR Cas9 molecules into primary T cells with unmatched efficiencies and minimal effect on viability. This capability substantially increases the yield of engineered cells in the cell therapy products, reducing the probability of product failure during manufacturing. 

The poster reflecting this research was presented at Next Generation CAR & T Cell Therapies conference this quarter.